Cargando…
Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial
BACKGROUND: Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and eff...
Autores principales: | Hylander, Terese, Larsson, Olivia, Petersson-Westin, Ulla, Eriksson, Mia, Kumlien Georén, Susanna, Winqvist, Ola, Cardell, Lars-Olaf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728811/ https://www.ncbi.nlm.nih.gov/pubmed/26817454 http://dx.doi.org/10.1186/s12931-016-0324-9 |
Ejemplares similares
-
Intralymphatic Immunotherapy (ILIT) with both grass and birch allergen- a randomized controlled trial
por: Hellkvist, Laila, et al.
Publicado: (2015) -
Inverse Immunological Responses Induced by Allergic Rhinitis and Head and Neck Squamous Cell Carcinoma
por: Millrud, Camilla Rydberg, et al.
Publicado: (2014) -
Deprived TLR9 Expression in Apparently Healthy Nasal Mucosa Might Trigger Polyp-Growth in Chronic Rhinosinusitis Patients
por: Tengroth, Lotta, et al.
Publicado: (2014) -
Downregulation of epithelial MHC II expression in chronic rhinosinusitis with polyps
por: Arebro, Julia, et al.
Publicado: (2013) -
Antigen presenting epithelial cells play a pivotal role in airway allergy
por: Arebro, Julia, et al.
Publicado: (2015)